Summary

Among statin-naïve patients with non-ST-segment elevation acute coronary syndrome managed with an early invasive strategy, pretreatment with high-dose rosuvastatin was associated with a significant reduction in the incidence of contrast-induced acute kidney injury. In addition, pretreatment with rosuvastatin was also associated with a reduction in adverse clinical events at 30 days compared with placebo. This article presents the results of the Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients With Acute Coronary Syndrome study [PRATO-ACS; NCT01185938].